Calithera Biosciences (CALA) Stock Price, News & Analysis

Company Overview

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.0072 to $0.0072
• 50-Day Range: $0.00 to $0.05
• 52-Week Range: $0.00 to $0.12
• Volume: 12 shs
• Average Volume: 575 shs
• Market Capitalization: $35,064.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CALA Stock Analysis - Frequently Asked Questions

How have CALA shares performed this year?

Calithera Biosciences' stock was trading at $0.03 at the start of the year. Since then, CALA stock has decreased by 76.0% and is now trading at $0.0072.
View the best growth stocks for 2024 here.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) posted its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter.

When did Calithera Biosciences' stock split?

Calithera Biosciences shares reverse split on the morning of Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Calithera Biosciences?

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX) and First Solar (FSLR).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CALA
• CUSIP: N/A
• CIK: 1496671
• Web: www.calithera.com
• Phone: (650) 870-1000
• Fax: N/A
• Employees: 60
• Year Founded: 2010

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $9.75 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.40) per share
• Price / Book: -0.02

Miscellaneous

• Outstanding Shares: 4,870,000
• Free Float: 4,550,000
• Market Cap: $35,064.00
• Optionable: Not Optionable
• Beta: -1.09